Beam Therapeutics BEAM Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$94.32M+12.9% | —— | -$112.73M-16.6% | -$103.23M-13.4% | -$108.33M-9.8% | ||
| $5.61M+1.4% | $5.67M+4.1% | $5.56M+1.6% | $5.54M-0.7% | $5.53M+1.8% | ||
| $19.04M-28.6% | $20.45M-32.3% | $22.75M-23.0% | $24.37M-22.9% | $26.68M-8.9% | ||
| $2.22M-41.6% | $1.19M— | —— | $2.64M+49.1% | $3.79M+195% | ||
| -$16.26M+11.9% | $14.3M+451% | —— | —— | -$18.46M+24.0% | ||
| $31.86M+65,122% | -$59K-101% | -$1.63M+6.8% | -$2.78M+55.5% | -$49K-101% | ||
| $134K+251% | -$91K-514% | -$93K— | -$57K— | -$89K-115% | ||
| -$6.36M+14.9% | -$113.82M-2,146% | -$5.66M+57.3% | -$8.47M+24.9% | -$7.47M-8.1% | ||
| $16K+101% | —— | $4.94M+339% | $4.42M+158% | -$2.08M+37.9% | ||
| —— | —— | —— | —— | —— | ||
| -$3.49M-6.0% | -$3.5M-6.9% | -$3.38M+1.5% | -$3.33M-6.1% | -$3.3M-6.1% | ||
| $35K— | —— | —— | —— | $0— | ||
| -$514K-2,004% | —— | -$1M-3,804% | $28K+102% | $27K-79.7% | ||
| -$128.51M-23.7% | -$83.29M-9.1% | -$81.48M+7.5% | -$76.45M+7.9% | -$103.88M-4.1% | ||
| $2.23M-27.2% | $3.73M+25.7% | $5.01M+218% | $3.14M+59.9% | $3.07M+25.7% | ||
| $153.79M-54.7% | $361.04M— | $175.64M+12.1% | $333.94M+148% | $339.17M+73.7% | ||
| $181.29M-16.5% | —— | —— | $166.67M-25.6% | $217.15M+50.6% | ||
| —— | $63.79M— | $63.79M— | $63.79M— | $63.79M— | ||
| $25.27M+120% | —— | —— | -$170.41M-295% | -$125.09M-134% | ||
| $93.89M— | —— | —— | —— | $0— | ||
| $2.03M+182% | $1.89M-45.3% | $412K+72.4% | $1.76M+631% | $719K-57.1% | ||
| $813K— | —— | —— | —— | $0— | ||
| $96.61M-79.6% | $1.89M-45.2% | $1.68M+32.7% | $1.11M+734% | $473.38M+16,240% | ||
| -$6.64M-103% | $27M— | -$14.15M+77.2% | -$245.75M— | $244.41M+263% | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| $35K— | —— | —— | —— | $0— | ||
| -$514K-2,004% | —— | -$1M-3,804% | $28K+102% | $27K-79.7% | ||
| $2.53M-4.4% | $2.52M+1.7% | $2.57M+5.5% | $2.65M+10.6% | $2.65M+12.2% | ||
| $2.5M-21.9% | $50K— | -$2.76M-1,279% | $1.15M-79.1% | $3.2M+210% | ||
| —— | $63.79M— | $63.79M— | $63.79M— | $63.79M— | ||
| $16K+101% | —— | $4.94M+339% | $4.42M+158% | -$2.08M+37.9% | ||
| -$16.26M+11.9% | $14.3M+451% | —— | —— | -$18.46M+24.0% | ||
| -$3.49M-6.0% | -$3.5M-6.9% | -$3.38M+1.5% | -$3.33M-6.1% | -$3.3M-6.1% | ||
| $134K+251% | -$91K-514% | -$93K— | -$57K— | -$89K-115% | ||
| $31.86M+65,122% | -$59K-101% | -$1.63M+6.8% | -$2.78M+55.5% | -$49K-101% | ||
| $2.76M-28.2% | $3.26M-29.8% | $4.23M-24.7% | $4.62M-22.1% | $3.85M-41.5% | ||
| $181.29M-16.5% | $218.03M+68.7% | $240.64M+31.5% | $166.67M-25.6% | $217.15M+50.6% | ||
| —— | $63.79M— | $63.79M— | $63.79M— | $63.79M— | ||
| $813K— | —— | —— | —— | $0— | ||
| —— | $0— | $0— | $0— | $0— | ||
| $1.51M+0.6% | —— | $1.26M+3.2% | —— | $1.5M+7.4% | ||
| $1.39M-4.4% | —— | $2.15M— | —— | $1.46M+306% | ||
| $0-100% | —— | —— | —— | $641K— | ||
| -$3.49M-6.0% | -$3.5M-6.9% | -$3.38M+1.5% | -$3.33M-6.1% | -$3.3M-6.1% | ||
| —— | $1.93M— | $1.93M— | $1.93M— | $1.93M— | ||
| -$130.75M-22.2% | -$87.02M-9.7% | -$86.49M+3.6% | -$79.59M+6.3% | -$106.95M-4.7% | ||
| -$130.75M-22.2% | -$87.02M-9.7% | -$86.49M+3.6% | -$79.59M+6.3% | -$106.95M-4.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Beam Therapeutics generate?
- Beam Therapeutics (BEAM) generated -$369.7M in operating cash flow over the trailing twelve months.
- What is Beam Therapeutics's free cash flow?
- After $14.1M of capital expenditures, Beam Therapeutics's free cash flow was -$383.8M over the trailing twelve months, down 6.3% year over year.
- Where does Beam Therapeutics's cash flow data come from?
- Every line is extracted from Beam Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
